» Articles » PMID: 25058446

Prediction of Binding Affinity and Efficacy of Thyroid Hormone Receptor Ligands Using QSAR and Structure-based Modeling Methods

Overview
Specialties Pharmacology
Toxicology
Date 2014 Jul 25
PMID 25058446
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The thyroid hormone receptor (THR) is an important member of the nuclear receptor family that can be activated by endocrine disrupting chemicals (EDC). Quantitative Structure-Activity Relationship (QSAR) models have been developed to facilitate the prioritization of THR-mediated EDC for the experimental validation. The largest database of binding affinities available at the time of the study for ligand binding domain (LBD) of THRβ was assembled to generate both continuous and classification QSAR models with an external accuracy of R(2)=0.55 and CCR=0.76, respectively. In addition, for the first time a QSAR model was developed to predict binding affinities of antagonists inhibiting the interaction of coactivators with the AF-2 domain of THRβ (R(2)=0.70). Furthermore, molecular docking studies were performed for a set of THRβ ligands (57 agonists and 15 antagonists of LBD, 210 antagonists of the AF-2 domain, supplemented by putative decoys/non-binders) using several THRβ structures retrieved from the Protein Data Bank. We found that two agonist-bound THRβ conformations could effectively discriminate their corresponding ligands from presumed non-binders. Moreover, one of the agonist conformations could discriminate agonists from antagonists. Finally, we have conducted virtual screening of a chemical library compiled by the EPA as part of the Tox21 program to identify potential THRβ-mediated EDCs using both QSAR models and docking. We concluded that the library is unlikely to have any EDC that would bind to the THRβ. Models developed in this study can be employed either to identify environmental chemicals interacting with the THR or, conversely, to eliminate the THR-mediated mechanism of action for chemicals of concern.

Citing Articles

Gene-environment interactions within a precision environmental health framework.

Motsinger-Reif A, Reif D, Akhtari F, House J, Campbell C, Messier K Cell Genom. 2024; 4(7):100591.

PMID: 38925123 PMC: 11293590. DOI: 10.1016/j.xgen.2024.100591.


SAG-DTA: Prediction of Drug-Target Affinity Using Self-Attention Graph Network.

Zhang S, Jiang M, Wang S, Wang X, Wei Z, Li Z Int J Mol Sci. 2021; 22(16).

PMID: 34445696 PMC: 8396496. DOI: 10.3390/ijms22168993.


In Silico Models to Predict the Perturbation of Molecular Initiating Events Related to Thyroid Hormone Homeostasis.

Garcia de Lomana M, Weber A, Birk B, Landsiedel R, Achenbach J, Schleifer K Chem Res Toxicol. 2020; 34(2):396-411.

PMID: 33185102 PMC: 7887800. DOI: 10.1021/acs.chemrestox.0c00304.


Chemical Screening of Nuclear Receptor Modulators.

Ishigami-Yuasa M, Kagechika H Int J Mol Sci. 2020; 21(15).

PMID: 32752136 PMC: 7432305. DOI: 10.3390/ijms21155512.


Evaluating Chemicals for Thyroid Disruption: Opportunities and Challenges with in Vitro Testing and Adverse Outcome Pathway Approaches.

Noyes P, Paul Friedman K, Browne P, Haselman J, Gilbert M, Hornung M Environ Health Perspect. 2019; 127(9):95001.

PMID: 31487205 PMC: 6791490. DOI: 10.1289/EHP5297.


References
1.
Low Y, Sedykh A, Fourches D, Golbraikh A, Whelan M, Rusyn I . Integrative chemical-biological read-across approach for chemical hazard classification. Chem Res Toxicol. 2013; 26(8):1199-208. PMC: 3818153. DOI: 10.1021/tx400110f. View

2.
Boas M, Feldt-Rasmussen U, Main K . Thyroid effects of endocrine disrupting chemicals. Mol Cell Endocrinol. 2011; 355(2):240-8. DOI: 10.1016/j.mce.2011.09.005. View

3.
Friesner R, Banks J, Murphy R, Halgren T, Klicic J, Mainz D . Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004; 47(7):1739-49. DOI: 10.1021/jm0306430. View

4.
Shoemaker T, Kono T, Mariash C, Evans-Molina C . Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs?. Endocr Pract. 2012; 18(6):954-64. PMC: 3745011. DOI: 10.4158/EP12086.RA. View

5.
Rucker C, Rucker G, Meringer M . y-Randomization and its variants in QSPR/QSAR. J Chem Inf Model. 2007; 47(6):2345-57. DOI: 10.1021/ci700157b. View